Gastric cancer immunosuppressive microenvironment heterogeneity: implications for therapy development

  • Trends Cancer. 2024 Jul;10(7):627-642. doi: 10.1016/j.trecan.2024.03.008.
Tadahito Yasuda  1 ,  Y Alan Wang  2
Affiliations
  • 1. Brown Center for Immunotherapy, Department of Medicine, Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, IN 46202, USA. Electronic address: [email protected].
  • 2. Brown Center for Immunotherapy, Department of Medicine, Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, IN 46202, USA. Electronic address: [email protected].
PMID: 38600020 DOI: 10.1016/j.trecan.2024.03.008
Abstract

Although immunotherapy has revolutionized solid tumor treatment, durable responses in gastric Cancer (GC) remain limited. The heterogeneous tumor microenvironment (TME) facilitates immune evasion, contributing to resistance to conventional and immune therapies. Recent studies have highlighted how specific TME components in GC acquire immune escape capabilities through cancer-specific factors. Understanding the underlying molecular mechanisms and targeting the immunosuppressive TME will enhance immunotherapy efficacy and patient outcomes. This review summarizes recent advances in GC TME research and explores the role of the immune-suppressive system as a context-specific determinant. We also provide insights into potential treatments beyond checkpoint inhibition.

Keywords
TME-based clinical trial; gastric cancer; peritoneal metastasis; single-cell analysis.
Products